620 results on '"Musso, Maurizio"'
Search Results
2. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
3. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
4. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
5. Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study.
6. Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
7. Chemical constitution of polyfurfuryl alcohol investigated by FTIR and Resonant Raman spectroscopy
8. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi
9. Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study
10. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials.
11. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
12. Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients
13. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
14. Synthesis, Crystal Chemistry, and Electrochemical Properties of Li7–2x La3Zr2–x Mo x O12 (x = 0.1–0.4): Stabilization of the Cubic Garnet Polymorph via Substitution of Zr4+ by Mo6+
15. Synthesis, Crystal Chemistry, and Electrochemical Properties of Li(7-2x)La3Zr(2-x)Mo(x)O12 (x = 0.1-0.4): Stabilization of the Cubic Garnet Polymorph via Substitution of Zr(4+) by Mo(6+).
16. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
17. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
18. Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy.
19. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
20. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation : An Italian Prospective Multicenter Survey
21. S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY
22. S228: POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).
23. P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
24. P1539: INFECTION-RELATED MORTALITY CLINICAL-BIOLOGICAL SCORING SYSTEM (IRM-SCORE) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VALIDATION STUDY IN GITMO CENTRES
25. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials
26. Determination of the temperatures of the γ, β and α relaxation processes in nylon 6,6 by Raman spectroscopy
27. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials
28. Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
29. Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
30. Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
31. Supplementary Figure 5 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
32. Supplementary Figure 1 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
33. Supplementary Figure 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
34. Charge Separation in BaTiO 3 Nanocrystals: Spontaneous Polarization Versus Point Defect Chemistry
35. Titania hybrid carbon spherogels for photocatalytic hydrogen evolution
36. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study
37. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
38. Industrial view of plasmonic devices made by nanoimprint or injection molding.
39. Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT
40. Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study
41. Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
42. Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis
43. Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
44. Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
45. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
46. Supportive care services in hemato-oncology centers: a national survey
47. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
48. Self-Assembled Au Nanoparticle Monolayers on Silicon in Two- and Three-Dimensions for Surface-Enhanced Raman Scattering Sensing
49. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
50. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.